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Summary The metabolism of cholesterol has been investigated in tumour cells, ascitic fluid and blood serum
during the growth of an ascites hepatoma (Yoshida AH-130) in the rat. High rates of cholesterol synthesis and
elevated free and esterified cholesterol content were observed in tumour cells. During tumour growth, the host
animals progressively developed marked changes in the level and distribution of serum cholesterol consisting in
an increase of total cholesterol and of a marked reduction of HDL cholesterol (HDL2 subfraction in
particular). In agreement with previous observations, these findings indicate that a consistent pattern ofaltered
cholesterol homeostasis develops in relation to normal or neoplastic tissue growth. High synthetic rates and
intracellular accumulation of cholesterol are observed in the proliferating cells. Moreover, blood serum
cholesterol decreases in the HDL fraction while it increases in LDLs, suggesting that during proliferative
processes cholesterol fluxes between tissues and serum lipoproteins are markedly perturbed.
Alterations of cholesterol metabolism have been consistently
observed in a variety of experimental tumour models (Col-
eman & Lavietes, 1981; Van Blitterswijk et al., 1985;
Clayman et al., 1986; Erickson et al., 1988) as well as in
human neoplasias (Gebhard et al., 1987). These alterations
include an increase in cholesterol content, associated with
enhanced rates of de novo cholesterol synthesis and deregula-
tion at the level of hydroxy-methyl-glutarylcoenzyme A
reductase (HMGR), the rate limiting enzyme in sterol syn-
thesis. It has been suggested that such changes could be
related to an increased requirement of cholesterol for new
membrane biogenesis that accompany cell growth (Coleman
& Lavietes, 1981). More recently, however, the possibility
that an increased production of mevalonate and its non-
sterol isoprenoid products is needed in the initiating phases
of DNA replication has been also proposed (Habenicht et al.,
1980; Siperstein, 1984). Similar patterns of intracellular
cholesterol metabolism were found in the hepatic hyperplasia
induced by a potent mitogen, lead nitrate (Dessi et al., 1984),
and in regenerating liver after partial surgical hepatectomy
(Dessi et al., 1986). These similarities indicate that the above
changes in cholesterol metabolism are related to cell pro-
liferation per se, rather than to tumour growth in particular.
Hepatic hyperplasia was characterised by peculiar alterations
of cholesterol distribution also in the plasma compartment,
namely a decrease in HDL cholesterol as well as in the
HDL2/HDL3 ratio (Dessi et al., 1986; 1989).
Cholesterol metabolism in the body is regulated through a
complex series of transport and biosynthetic mechanisms,
which rely on the continuous exchange of cholesterol
between tissues and blood. It is thus conceivable that any
substantial alteration in the metabolism of cholesterol at the
cellular level (e.g. during cell proliferation) may entail
changes in the plasmatic pools of cholesterol.
In the present study, cholesterol metabolism was inves-
tigated in tumour cells and in the blood compartment in rats
during the growth of a highly deviated fast growing ascites
hepatoma (Yoshida AH-130).
The study was made at different time intervals after
tumour transplantation in order to evaluate the alterations
occurring in the malignant cells and whether these were
associated with changes in the cholesterol distribution in the
plasma of the host animal, as already observed in different
models of cell proliferation (Dessi et al., 1986; 1989).
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Materials and methods
Animals
Male Wistar rats (Nossan, Milan, Italy), weighing approx-
imately 200-250 g and maintained on a regular light-dark
cycle (light 08:00-20:00h) were used in these experiments.
The Yoshida ascites hepatoma AH-130 was routinely
maintained by weekly intraperitoneal transplantation of app-
rox. 3.10' cells. For the present experiments, rats were
injected with 108 cells from exponentially growing tumours
(Tessitore et al., 1987). As previously reported (Tessitore et
al., 1987), for about 6 days after an intraperitoneal inoculum
of 108 cells, the Yoshida ascites hepatoma AH-130 grows
exponentially with a doubling time of 1 day; then growth
slows down and after day 8 the tumour enters a quasi-
stationary state, wherein a sizeable cell turnover contributes to
the maintenance of a virtually constant population size. The
tumour is uniformly lethal 14-16 days after transplantation.
Rats had free access to a balanced semi-synthetic diet
(Piccioni, Brescia, Italy) and water. They were fasted over-
night before sacrifice at 4, 7 and 10 days after inoculation of
the tumour cells. Food consumption was 18-20 g/rat/day at
the start of the experiments, and it declined progressively to
about lOg/rat/day 10 days after tumour transplantation.
At specific times, rats were anaesthesised with diethyl
ether, blood was collected from the aorta and tumour cells
were taken from the peritoneal cavity and separated from the
ascitic fluid by centrifugation at lOOg for 10min; liver was
excised, weighed and immediately processed for further
analysis. Since no significant variations in the parameters
considered were observed in control animals over the period
of the experiment (10 days), values obtained from all rats
sacrificed in this group at different time points were pooled.
The amount of ascitic fluid was sufficient for biochemical
analysis starting at day 7 after tumour transplantation.
DNA synthesis
For determination of DNA synthesis, AH-130 cells with-
drawn from the peritoneal cavity, were washed with
phosphate-buffered saline (PBS), suspended in DMEM
buffered with 20mm 4-(2-hydroxyethyl)-l-piperazine-ethane-
sulfonic acid (Hepes) at pH 7.4 and incubated in a shaking
bath at 370C for 2 h in the presence of 3H-thymidine
(10 liCiml-'); specific activity 25 Cimmolh , New England
Nuclear, Boston, USA). For 3H-thymidine incorporation into
DNA, samples in triplicate were automatically harvested
onto glass filters using an harvester (Flow, Irvine, Scotland),
and the radioactivity was counted in a scintillation counter
(Beckman, USA) using Biofluor (New England Nuclear, Bos-
ton) as scintillation fluid.
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Cholesterol synthesis
For cholesterol synthesis determination, 3H20 incorporation
into cholesterol was measured in vitro in both liver and
AH-130 tumour cells. Livers were cut into thin slices (1 mm
thick) and tumour cells were processed as described above.
For the assay 500 mg of tissue slices or 2 x 107 cells were
placed in glass tubes containing Krebs' bicarbonate buffer
and 10 mCi of 3H20 (New England Nuclear, Boston, MA) in
an atmosphere of 95% 02:5% CO2 and incubated at 37°C
for 2h. After incubation tissues and tumour cells were
saponified with alcoholic KOH, the nonsaponifiable lipids
were then extracted, and sterol precipitated with digitonin.
The pellets of washed digitonides were dried under a stream
of nitrogen and dissolved with absolute ethanol. Suitable
aliquots of the ethanol solution were used to determine
cholesterol content (Bowman & Wolf, 1962) and for
measurement of radioactivity using Econofluor as solvent.
Analytic procedures
To determine free and esterified cholesterol content in livers
and tumour cells, total lipids were extracted according to
Folch et al. (1957), and neutral lipids separated by thin-layer
chromatography (DC-Alufolien Kiesegel 60, Merck, Darm-
stadt, FRG), using the solvent system n-heptane/isopropyl-
ether/formic acid (60:40:2), v/v). The spots of free and
esterified cholesterol were then extracted and cholesterol con-
tent determined according to Bowman and Wolf (1962) using
cholesterol and cholesterol palmitate (Sigma Chemical, St
Louis, MO), as standard.
DNA content was measured according to Boer (1975) and
protein by the method of Lowry et al. (1951) using sperm
DNA and bovine serum albumin as the working standards,
respectively.
The presence of tumour necrosis factor (TNF) in the blood
plasma was tested on L929 cells according to Flick and
Gifford (1984); one unit of activity was defined as the reci-
procal dilution required to produce a 50% decrease in absor-
bance relative to control cells exposed to actinomycin alone.
Cholesterol, triglyceride and phospholipid concentrations
in serum and ascitic fluid were estimated using reagents
obtained commercially (Boehringer, Mannheim, FRG). Very
low density lipoproteins (VLDL) and LDL were isolated
from serum and ascitic fluid by precipitations with a mixture
of phosphotungstic acid and magnesium ions. After standing
for 10min at room temperature, the mixtures were centri-
fuged at 10,000 g for 10min, the supernatant containing the
HDL fraction was removed and the levels of cholesterol,
triglyceride and phospholipid were determined. The pre-
cipitate containing VLDL and LDL fractions was dissolved
in 0.15 M NaCl and the level of cholesterol, triglyceride and
phospholipid was estimated as above. Proteins in VLDL +
LDL and HDL subfractions were determined according to.
Lowry et al. (1951).
Apoproteins in VLDL + LDL and in HDL were separated
by high-performance liquid chromathography (HPLC). One
hundred jil of the VLDL + LDL and HDL fractions were
added to 1 ml of 0.1 M sodium phosphate buffer pH 7.0
containing 0.1% sodium dodecyl sulphate (SDS) according to
Okazaky et al. (1984).
The mixed solution was incubated at 60°C for 5 min and
then used for HPLC analysis. Standard proteins (SDS
molecular weight markers ranging from 14,000 to 70,000
purchased from Sigma) were dissolved in the same buffer and
similarly incubated at 60°C for 5 min. Apoproteins of appar-
ent molecular weight <14,000 to 60,000 were resolved on
HPLC with aqueous gel permeation column (TSK-GEL,
Toyo Soda). HPLC conditions in these experiments were as
follows: Column: G 3000 SW (column size, 7.5 mm
ID x 600 mm); eluant, 0.1 M sodium phosphate buffer
(pH 7.0) containing 0.1% SDS; flow rate, 0.3 ml min; applied
volume, 175 glI). Eluted proteins were detected spectro-
photometrically at 280 nm.
Statistical evaluations
Statistical comparisons of two means were made with the
Student's t-test. Multiple comparisons were computed using
one-way analysis of variance.
Results
A slight decrease in body weight was evident in rats 4 days
after tumour transplantation, while this change was more
marked at 7 and 10 days (Table I).
DNA and cholesterol synthesis in tumour cells during the
growth of Yoshida ascites hepatoma AH-130 are shown in
Table II.
The incorporation of 3H-thymidine in tumour cells steadily
declined from day 4 to day 10, when the AH-130 tumour
entered a stationary phase of growth. The maximum incor-
poration of 3H20 into cholesterol was reached at 7 days after
Table I Body weight in control and AH-130 tumour-bearing rats
Days after tumour
transplantation 4 7 10
Initial body weight (g) 200 ± 8 (32)
Body weight at sacrifice (g)
(Control) 225 ± 11 (4) 240 ± 17 (3) 265 ± 15 (3)
Body weight at sacrifice (g)
(Tumour-bearing rats) 193 ± 12 (7) 144 ± 9 (7) 128 ± 7 (8)
Tumour vs control P<0.05 P<0.01 P<0.01
The values represent the mean ± s.e. (number of animals in parenthesis).
Table II DNA and cholesterol synthesis in the Yoshida ascites hepatoma
AH-130
3H-thymidine 3H20
Time after tumour incorporation into DNA incorporation into cholesterol
transplantation (dpm x 1031mg DNA) (dpm/2 x 10' cells)
4 days (5) 6877 ± 649 608 ± 63
7 days (5) 3951 ± 582 875 + 87
10 days (5) 1169± 334 648 ± 55
4 days vs 7 days P<0.05 P<0.05
4 days vs 10 days P<0.05 n.s.
Variance analysis P<0.01 P<0.05
The values represent the mean ± s.e. (number of animals in parenthesis).CHOLESTEROL METABOLISM IN TUMOUR CELLS 789
tumour transplantation. As shown in Table III a significant
increase of free cholesterol content in AH-130 cells was
observed 10 days after tumour transplantation while
cholesterol esters increased progressively from day 4 to day
10, thus resulting in an increase in the percentage of
cholesterol esters in tumour cells. In livers of AH-130
tumour-bearing rats free cholesterol content decreased
significantly while cholesterol esters increased when com-
pared to normal liver (Table IV). These changes in liver
cholesterol content were associated with a significant decrease
of hepatic cholesterol synthesis at day 4 and 7 after tumour
transplantation.
The lipid and protein content of whole plasma collected
from control and hepatoma-bearing rats is presented in Table
V. While plasma protein slightly decreased, the levels of all
lipid classes were elevated in tumour-bearing animals.
In Table VI and VII the distribution of lipid classes and
proteins among HDL and VLDL + LDL fractions is shown.
All lipid classes and proteins are elevated in VLDL + LDL at
all time points considered. In contrast, the HDL fraction
revealed a significant drop in the level of all lipid classes and
proteins, with the exception oftriglycerides, which showed an
increase. In ascitic fluid, HDL cholesterol accounted for
29.5% of total cholesterol at day 7; this value dropped to
15.3% at 10 days. No significant changes in other lipid
parameters were observed in ascitic fluid between day 7 and
10, except for an increase in phospholipids in VLDL + LDL
fractions at 10 days compared to 7 days (Table VIII).









4 days (6) 39.96 ± 4.66 9.76 ± 1.42 21.18 ± 3.00
7 days (5) 35.60 ± 3.80 17.98 ± 0.65 34.05 ± 2.13
10 days (8) 58.07 ± 7.29 21.70 ± 1.49 38.43 ± 2.13
4 days vs 7 days n.s P<0.01 P<0.01
4 days vs 10 days P<0.05 P<0.01 P<0.05
Variance analysis P<0.05 P<0.01 P<0.01
The values represent the mean ± s.e. (number of animals in parenthesis).
Table IV Hepatic cholesterol synthesis in control and AH-130 tumour-bearing rats
3H20 incorporation
Time after tumour into liver cholesterol Cholesterol (mgg-' liver)
transplantation (dpm tg-' chol.) Total Free Ester Ester (%)
Control (10) 3.41 ± 0.58 1.80 ± 0.15 1.41 ± 0.14 0.39 ± 0.02 23.07 ± 1.95
4 days (4) 2.32 ± 0.40 0.74 ± 0.01 0.49 ± 0.05 0.24 ± 0.01 33.18 ± 6.25
7 days (5) 2.26±0.80 1.09 0.21 0.44 0.01 0.66±0.14 59.18± 2.10
10 days (8) 3.06 ± 0.68 1.21 ± 0.15 0.67 ± 0.01 0.53 ± 0.01 44.69 ± 3.54
Control vs 4 days P<0.01 P<0.01 P<0.01 P<0.05 n.s.
Control vs 7 days P<0.01 P<0.05 P<0.01 P<0.05 P<0.01
Control vs 10 days n.s. P<0.05 P<0.01 n.s. P<0.01
P<0.01 P<0.01 P<0.01 P<0.05 P<0.01
The values represent the mean ± s.e. (number of animals in parenthesis).
Table V Lipid and protein distribution in serum from control and AH-130-tumour-bearing
rats
Time after tumour Cholesterol Triglyceride Phospholipid Protein
transplantation (mgdl-') (mgdl-') (mgdl ') (mgml-')
Control (7) 55.24 ± 2.30 40.78 ± 9.01 68.27 ± 4.71 59.30 ± 3.05
4 days (7) 70.57 ± 5.20 85.05 ± 8.61 61.77 ± 4.54 52.48 ± 1.75
7 days (6) 107.05 15.86 144.18 23.13 99.19 20.36 47.41 ± 1.54
10 days (5) 121.40 13.04 292.76 28.45 119.51 ± 14.13 52.90 2.27
Control vs 4 days P<0.05 P<0.01 n.s. n.s.
Control vs 7 days P<0.01 P<0.01 P<0.01 P<0.01
Control vs 10 days P<0.01 P<0.01 P<0.01 n.s.
Variance analysis P<0.01 P<0.01 P<0.01 P<0.05
The values represent the mean ± s.e. (number of animals in parenthesis).
Table VI Lipid and protein composition of HDL lipoproteins in control and
AH-130-tumour-bearing rats
Time after tumour Cholesterol Triglyceride Phospholipid Protein
transplantation (mg dl-') (mg dl-') (mg dl-') (mgml-')
Control (7) 42.24 1.71 14.09 2.15 51.32 3.31 55.16 2.60
4 days (7) 29.01 ± 2.98 28.30 ± 5.26 38.16 ± 3.72 46.80 ± 1.07
7 days (6) 27.87 ± 2.89 22.52 ± 2.82 38.23 ± 5.08 39.35 ± 1.64
10 days (5) 39.67 ± 2.79 50.80 ± 7.12 49.42 ± 4.09 43.65 ± 1.65
Control vs 4 days P<0.01 P<0.05 P<0.05 P<0.01
Control vs 7 days P<0.01 P<0.05 P<0.05 P<0.05
Control vs 10 days n.s. P<0.01 n.s. P<0.01
Variance analysis P<0.01 P<0.01 P<0.05 P<0.01
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Table VII Lipid and protein composition of VLDL + LDL lipoproteins in control and
AH-130-tumour-bearing rats
Time after tumour Cholesterol Triglyceride Phospholipid Protein
transplantation (mg dl-') (mg dl-') (mg dl-') (mgml-')
Control (7) 13.00 ± 1.77 29.58 ± 9.15 8.02 ± 2.06 4.14 ± 1.09
4 days (7) 41.56 + 4.59 56.34 ± 6.84 35.60 ± 4.73 4.25 ± 0.91
7 days (6) 79.34 13.45 121.66 23.02 90.97 5.53 8.06 0.51
10 days (5) 94.80 ± 25.72 242.08 ± 24.43 70.08 ± 13.63 9.28 ± 0.92
Control vs 4 days P<0.01 P<0.05 P<0.01 n.s.
Control vs 7 days P<0.01 P<0.01 P<0.01 P<0.05
Control vs 10 days P<0.01 P<0.01 P<0.01 P<0.01
Variance analysis P<0.01 P<0.01 P<0.01 P<0.01
The values represent the mean ± s.e. (number of animals in parenthesis).
Table VIII Lipid and protein composition ofHDL and VLDL + LDL lipoproteins in ascitic
fluid from AH-130-tumour-bearing rats
HDL HDL HDL HDL
Time after tumour cholesterol triglyceride phospholipid protein
transplantation (mg dl-') (mg dl-') (mg dl-') (mgml-')
7 days (6) 9.26 ± 1.54 21.74 ± 2.20 34.96 ± 3.28 35.17 ± 2.75
10 days (6) 5.13 0.42 24.41 ±2.15 29.09 2.04 39.88 1.53
7 days vs 10 days P<0.05 n.s. n.s. n.s.
VLDL + LDL VLDL + LDL VLDL + LDL VLDL + LDL
7 days (6) 22.11 ± 3.66 7.79 ± 2.19 8.96 ± 2.00 7.39 ± 0.66
10 days (6) 28.33 ± 2.80 19.54 ± 5.28 15.21 ± 1.65 7.35 ± 0.78
7 days vs 10 days n.s. n.s. P<0.05 n.s.
The values represent the mean ± s.e. (number of animals in parenthesis).
The plasma concentration of TNF was 9-10 U ml' in
tumour bearing rats. No detectable concentration of TNF
was observed in plasma of control animals.
Proteins of apparent molecular weight <14,000-60,000
were resolved on HPLC. The apoprotein patterns of
VLDL + LDL and HDL lipoprotein fractions are shown for
both control and tumour-host serum in Figures 1 and 2.
Three commonly recognised apolipoproteins of rat serum are
clearly evident for HDL fraction: Apo A-IV, Apo Al and
Apo C, while Apo E and ApoC are evident in VLDL + LDL
fraction. In tumour bearing rats, HDL showed a decrease in
the protein profile corresponding to Apo A IV and Apo Al
at all time points considered, while a consistent increase in
Apo E was observed in the VLDL + LDL fraction.
Discussion
Alterations of cholesterol metabolism, including an increase
of cholesterol synthesis and an accumulation of cholesterol
esters in proliferating tissues associated with a decrease of
HDL cholesterol in serum, were previously found in different
experimental models of cell proliferation (Dessi et al., 1984;
1986; 1989).
The present study confirms and extends these observations
using as a model the rat ascites hepatoma AH-130, a rapidly
growing lethal tumour.
In this model the increase of cholesterol synthesis was
associated with a progressive accumulation of cholesterol in
growing AH-130 cells. Initially, the accumulation was mostly
due to an increased content in cholesterol esters, and later an
increase in free cholesterol was also observed. These findings
are consistent with several reports in the literature showing
that, in a variety of tumours, cell membranes are enriched in
free cholesterol (Feo et al., 1973) and that cholesterol esters
accumulate in tumour cells (Clayman et al., 1986; Rao et al.,
1983) or in the proliferating tissue (Dessi et al., 1984; 1986;
Fex & Wallinder, 1973).
The biological significance of such phenomena remains to
be established, nor is it clear whether the cholesterol
accumulated in tumour tissues derives from new synthesis
and/or increased uptake. However, it is likely that during
processes of rapid cell proliferation, cholesterol esters are
stored inside cells probably to meet the increased demand of
cholesterol for new membrane biogenesis.
Alterations of intracellular cholesterol metabolism were
accompanied by changes in total serum lipids and in lipo-
protein profiles. All plasma lipid classes were elevated. This
was due to an increase of lipid moietes in VLDL + LDL
while phospholipid and cholesterol in HDL fractions were
actually decreased.
Concomitantly, changes in host apoproteins were also
observed: Apo E increased in VLDL + LDL fractions, while
a decline in Apo Al and Apo AIV was observed in HDL
lipoproteins. The latter observation suggests that changes in
lipoprotein pattern in tumour-bearing rats may not be
entirely explained by alterations in the amount of lipids
bound to each lipoprotein class, but could also be related to
changes in the absolute number of circulating lipoprotein
particles.
The interpretation of our overall results is complicated
because the distribution of lipids in the different classes of
lipoproteins reflects the balance of lipids derived from
endogenous biosynthesis, catabolism, diet, mobilisation of
stored fat and the tumour itself.
In our model, tumour-bearing rats, developed a pronounc-
ed hypercholesterolemia and hypertriglyceridemia during the
total period of tumour growth. At least a few possibilities
can be considered to explain these findings: an increase
mobilisation of lipids from fat depots as evidenced by the
observed cachexia, a decreased catabolism of VLDL
mediated by TNF (Ettinger et al., 1990), being this vector
elevated in serum during tumour growth and finally, since an
increase in Apo E was also found, a decreased uptake by the
liver of VLDL and LDL via Apo E receptors must be also
considered. These three possibilities are not mutually exclus-
ive.
It appears unlikely that changes in diet and endogenous
biosynthesis may be involved under our experimental condi-
tions. Hepatic cholesterol synthesis and food intake, the two
main sources of plasma lipid under normal conditions, were
in fact both decreased in tumour-bearing rats.CHOLESTEROL METABOLISM IN TUMOUR CELLS 791
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Figure 1 Elution pattern of HDL apolipoproteins from normal and AH-130 tumour-bearing rats. Column: G3000SW
(600 x 7.5 nm I.D.). Eluent: 0.1M sodium phosphate buffer (pH 7.0) containing 0.1% SDS. Flow rate: 0.30 ml min-'. Load volume:
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Figure 2 Elution pattern of VLDL + LDL apolipoproteins from normal and AH-130 tumour-bearing rats. Column: G3000SW
(600 x 7.5 nm I.D.). Eluent: 0.1M sodium phosphate buffer (pH 7.0) containing 0.1% SDS. Flow rate: 0.30 ml min-'. Load volume:
175ji1. Peaks: 1 = Apo E, 2 = Apo C. (a) normal rats; (b) 4 days after tumour transplantation; (c) 7 days; (d) 10 days.
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In this model, HDL steadily decreased over the course of
tumour growth (4 and 7 days), then increased to near normal
levels at 10 days, a time coinciding with the stationary phase
of tumour growth. Thus it seems that the decrease in HDL
levels may be a specific response to cell proliferation rather
than directly related to the presence of tumour. A decrease of
HDL was previously observed in our laboratories in different
experimental models of cell proliferation, such as liver
regeneration after partial hepatectomy (Dessi et al., 1986),
bone marrow hyperplasia induced by phenylhydrazine (Dessi
et al., 1990) and more recently in patients with different types
of haematologic neoplasma (Dessi et al., 1991) and in G6PD
deficient children with bone marrow hyperplasia after
haemolysis induced by ingestion of fava bean (favism) (Dessi
et al., 1992). In these models, however, the decrease of HDL
was not associated with hyperlipidemia.
Taken together these findings suggest that the reported
changes in total plasma lipid concentrations do not reflect a
general pattern associated with growth, being variable and
dependent on the type of hyperplastic or neoplastic growth.
In contrast, the decrease in HDL fraction, virtually present in
all models of cell proliferation, seems to represent a general-
ised phenomenon related to rapid cell proliferative processes.
A major function attributed to HDL is the ability to
remove excess cholesterol from extrahepatic cells (Eisenberg,
1984). Since during proliferative processes the utilisation and
storage of cholesterol are increased in proliferating tissues, it
is possible to hypothesise that the observed decrease in HDL
may be caused, at least partially, by a reduced release of free
cholesterol from proliferating cells to HDL. Many studies in
vitro support this conclusion: the exposure to HDL results in
a net efflux of free cholesterol from various cultured cells
(Daerr et al., 1980; Daniels et al., 1980), this efflux being
partially blocked in rapidly proliferating cells and in trans-
formed cell lines (Gebhard et al., 1987; Pittman et al., 1987).
Furthermore, Oram et al. (1987) have demonstrated that
Apo AI-HDL binds to cell surface receptors and promotes
selective removal of excess cholesterol from intracellular
pool. The activity of these receptors is regulated by both the
availability of exogenous cholesterol and the growth state of
the cells.
Treatment of quiescent cells with serum growth factors
suppresses both HDL receptor activity and HDL-mediated
cholesterol efflux (Bierman et al., 1989). An opposite effect
was obtained by the treatment of cultured fibroblasts with
inhibitors of cell proliferation (Oppenheimer et al., 1988).
In line with these data, we have recently demonstrated that
the inhibition in vivo of cholesterol esters accumulation by a
specific inhibitor of ACAT, strongly prevents the decrease of
HDL normally found during proliferative processes (Anchisi
et al., (1990), giving support to the hypothesis that HDL
alterations in serum are dependent on the altered cholesterol
metabolism in proliferating tissues.
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